¼¼°èÀÇ ¿ì¿ïÁõ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Áúȯ À¯Çüº°, ¾àÁ¦ À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°(2025-2033³â)
Depression Drugs Market Report by Drug Class, Disorder Type, Drug Type, Distribution Channel, and Region 2025-2033
»óǰÄÚµå : 1675282
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 148 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

IMARC GroupÀº 2024³â ¼¼°è ¿ì¿ïÁõ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð°¡ 192¾ï ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç, 2025³âºÎÅÍ 2033³â±îÁö 2.9%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 2033³â¿¡´Â 251¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÁÂ½Ä »ýȰ½À°ü°ú ½ºÆ®·¹½º·Î ÀÎÇÑ ´ëÁßÀÇ ¿ì¿ïÁõ Áõ°¡, ¾à¹° Á¦ÇüÈ­ ¹× Àü´Þ ±â¼úÀÇ ¹ßÀü, ¸ð¹ÙÀÏ ¾Û ¹× ¿Â¶óÀÎ Ä¡·á Ç÷§Æû°ú °°Àº µðÁöÅÐ Ä¡·á ¼±È£µµ Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¿ì¿ïÁõÀº ±àÁ¤ÀûÀÎ °¨Á¤ÀÇ °á¿©, Ç×»ó ³·Àº ±âºÐ, ´Ù¾çÇÑ ÀÎÁöÀû, ½ÅüÀû, ÇൿÀû, Á¤¼­Àû Áõ»óÀ» Ư¡À¸·Î ÇÏ´Â Á¤½ÅÀå¾ÖÀÔ´Ï´Ù. Áõ»óÀ» È®ÀÎÇϰí ȯÀÚÀÇ º´·ÂÀ» È®ÀÎÇÏ¿© Áø´ÜÇÕ´Ï´Ù. ÀÌÈÄ ¿ì¿ïÁõ Ä¡·áÁ¦¸¦ »ç¿ëÇÏ¿© Ä¡·áÇÕ´Ï´Ù. ¿ì¿ïÁõ Ä¡·áÁ¦´Â ³ú ³» ¼¼·ÎÅä´Ñ°ú °°Àº ½Å°æÀü´Þ¹°ÁúÀÇ ÀÛ¿ëÀ» Á¶ÀýÇÏ¿© ȯÀÚÀÇ ±âºÐ°ú °¨Á¤À» Á¶ÀýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ºÒ¾È, °èÀý¼º Á¤¼­ Àå¾Ö, Á¶¿ïÁõÀÇ Áõ»óÀ» ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¿ì¿ïÁõÀº ½ÅüÀû Àå¾ÖÀÇ ÁÖ¿ä ¿øÀÎ Áß ÇϳªÀ̸ç, Àü ¼¼°èÀûÀ¸·Î 2¾ï 6,400¸¸ ¸í ÀÌ»óÀÌ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. »çȸ ºÒ¾È°ú ¿ì¿ïÁõ°ú °°Àº Á¤½ÅÀå¾ÖÀÇ À¯º´·ü Áõ°¡´Â ¿ì¿ïÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, °¢±¹ Á¤ºÎ°¡ Àü¸éÀûÀÎ ºÀ¼â¸¦ ½ÃÇàÇÏ°í »çȸÀû °Å¸®µÎ±â ¼ö´ÜÀ» µµÀÔÇÔ¿¡ µû¶ó Àα¸ÀÇ »ó´ç ºÎºÐÀÌ ÀÏ»ó »ýȰ¿¡ º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, ÀÌ´Â °³ÀÎÀÇ Á¤½Å°Ç°­¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¿ì¿ïÁõ Ä¡·áÁ¦ÀÇ ÆÇ¸Å¸¦ ÃËÁøÇÏ´Â ¶Ç ´Ù¸¥ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÎÀÛ¿ëÀÌ Àû°í Àå±âÀûÀÎ È¿°ú¸¦ ±â´ëÇÒ ¼ö ÀÖ´Â Ç׿ì¿ïÁ¦ °³¹ß¿¡ ÀÖ¾î »õ·Î¿î ±â¼úÀÇ ÃâÇöÀº »õ·Î¿î ¾à¹°¿¡ ´ëÇÑ ¼ö¿ë¼º Áõ°¡¿Í ÇÔ²² ÇâÈÄ ¸î ³âµ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

IMARC GroupÀÇ ÃֽŠº¸°í¼­´Â ¼¼°è ¿ì¿ïÁõ Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇÑ ¸ðµç Áß¿äÇÑ Ãø¸éÀ» ½ÉÃþÀûÀ¸·Î ºÐ¼®Çß½À´Ï´Ù. ½ÃÀå °Å½ÃÀû °³¿ä, ¾÷°è ½ÇÀûÀÇ ¹Ì½ÃÀû ¼¼ºÎ »çÇ×, ÃÖ±Ù µ¿Çâ, ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× °úÁ¦, SWOT ºÐ¼®, Portre's Five Forces ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼® µî ´Ù¾çÇÑ ³»¿ëÀ» ´ã°í ÀÖ½À´Ï´Ù. º» º¸°í¼­´Â ¾÷°è °ü°èÀÚ, ÅõÀÚÀÚ, ¿¬±¸¿ø, ÄÁ¼³ÅÏÆ®, ºñÁî´Ï½º Àü·«°¡, ±×¸®°í ¾î¶² ÇüÅÂ·Îµç ¿ì¿ïÁõ Ä¡·áÁ¦ ½ÃÀå¿¡ °ü¿©Çϰí Àְųª ÁøÃâÀ» °èȹÇϰí ÀÖ´Â ¸ðµç ºÐµé¿¡°Ô ²À ÇÊ¿äÇÑ º¸°í¼­ÀÔ´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ ¿ì¿ïÁõ Ä¡·áÁ¦ ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : ¾àÁ¦ Ŭ·¡½ºº°

Á¦7Àå ½ÃÀå ºÐ¼® : Áúȯ À¯Çüº°

Á¦8Àå ½ÃÀå ºÐ¼® : ¾àÁ¦ À¯Çüº°

Á¦9Àå ½ÃÀå ºÐ¼® : À¯Åë ä³Îº°

Á¦10Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global depression drugs market size reached USD 19.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.1 Billion by 2033, exhibiting a growth rate (CAGR) of 2.9% during 2025-2033. The growing cases of depression among the masses due to sedentary lifestyle and stress, increasing advancements in drug formulation and delivery techniques, and rising preferences for digital therapeutics, such as mobile apps and online therapy platforms, are some of the factors impelling the market growth.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

Breakup by Drug Class:

Breakup by Disorder Type:

Breakup by Drug Type:

Breakup by Distribution Channel:

Breakup by Region:

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Depression Drugs Market

6 Market Breakup by Drug Class

7 Market Breakup by Disorder Type

8 Market Breakup by Drug Type

9 Market Breakup by Distribution Channel

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porter's Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â